Format

Send to

Choose Destination
Clin Cancer Res. 2014 Sep 1;20(17):4422-4. doi: 10.1158/1078-0432.CCR-14-0932. Epub 2014 Jul 24.

"Companion diagnostics": has their time come and gone?

Author information

1
Department of Medicine and Pathology, University of Colorado Cancer Center, Aurora, Colorado. fred.hirsch@ucdenver.edu.
2
Department of Medicine and Pathology, University of Colorado Cancer Center, Aurora, Colorado.
3
Department of Medicine, Smillow Cancer Center, Yale School of Medicine, New Haven, Connecticut.

Abstract

Rapid development of molecularly targeted drugs requires a "companion diagnostic" that could delay drug development and limit availability of active drugs for relevant patients. Were the negative results from MetMab studies in patients with advanced non-small cell lung cancer due to drug failure or failure of the right companion diagnostic?

PMID:
25059519
PMCID:
PMC4155019
DOI:
10.1158/1078-0432.CCR-14-0932
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center